Generate Investment Management Ltd Has $15.95 Million Holdings in Boston Scientific Corporation $BSX

Generate Investment Management Ltd lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 27.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 254,250 shares of the medical equipment provider’s stock after selling 94,670 shares during the quarter. Generate Investment Management Ltd’s holdings in Boston Scientific were worth $15,954,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Brighton Jones LLC increased its stake in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $26,000. Main Street Financial Solutions LLC boosted its stake in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC grew its holdings in shares of Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its holdings in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 9,800 shares of company stock worth $554,012 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on BSX. UBS Group lowered their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Wells Fargo & Company reissued an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Jefferies Financial Group lowered their price target on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Stock Down 2.2%

Boston Scientific stock opened at $44.30 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company’s 50-day moving average is $54.37 and its 200-day moving average is $72.44. The firm has a market capitalization of $65.84 billion, a PE ratio of 18.53, a P/E/G ratio of 0.87 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $44.05 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the business posted $0.75 EPS. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.